Top Markets
Coin of the day
Almirall, S.A. Almirall, S.A.

Almirall, S.A.

ALM
Rang in aandelen #5431
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery,... Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.
Aandeelprijs
$12.43
Marktkapitalisatie
$2.71B
Verandering (1 dag)
-0.19%
Verandering (1 jaar)
-4.33%
Land
ES
Handel Almirall, S.A. (ALM)

Categorie

EPS voor Almirall, S.A. (ALM)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Almirall, S.A. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Almirall, S.A. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten